These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32804017)

  • 81. Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.
    Tutor O; Díaz MA; Ramírez M; Algara P; Madero L; Martínez P
    Leuk Res; 2002 Sep; 26(9):817-20. PubMed ID: 12127556
    [TBL] [Abstract][Full Text] [Related]  

  • 82. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
    Wang Y; Zeng HM; Zhang LP
    Ital J Pediatr; 2018 Aug; 44(1):94. PubMed ID: 30115129
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
    Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
    Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.
    Birts CN; Harding R; Soosaipillai G; Halder T; Azim-Araghi A; Darley M; Cutress RI; Bateman AC; Blaydes JP
    Biol Cell; 2010 Jan; 103(1):1-19. PubMed ID: 20964627
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The prognostic significance of hematogones in childhood B-cell acute lymphoblastic leukemia.
    Arabi S; Yousefian S; Kavosh A; Mansourian M; Nematollahi P
    Pediatr Blood Cancer; 2023 Feb; 70(2):e30138. PubMed ID: 36495254
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Preserved global histone H4 acetylation linked to ETV6-RUNX1 fusion and PAX5 deletions is associated with favorable outcome in pediatric B-cell progenitor acute lymphoblastic leukemia.
    Janczar K; Janczar S; Pastorczak A; Mycko K; Paige AJ; Zalewska-Szewczyk B; Wagrowska-Danilewicz M; Danilewicz M; Mlynarski W
    Leuk Res; 2015 Dec; 39(12):1455-61. PubMed ID: 26520622
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
    Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
    Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Expression of zinc finger protein X-linked in childhood B lineage acute lymphoblastic leukemia].
    Wang Z; Liang HH; Li BS; Huang XH; Zhang J; Wang X; Ding LX; Jiang H
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jul; 15(7):509-13. PubMed ID: 23866268
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
    Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
    Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia.
    Zhang H; Liu AP; Devidas M; Lee SH; Cao X; Pei D; Borowitz M; Wood B; Gastier-Foster JM; Dai Y; Raetz E; Larsen E; Winick N; Bowman WP; Karol S; Yang W; Martin PL; Carroll WL; Pui CH; Mullighan CG; Evans WE; Cheng C; Hunger SP; Relling MV; Loh ML; Yang JJ
    J Natl Cancer Inst; 2021 Apr; 113(4):408-417. PubMed ID: 32894760
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.
    Vidriales MB; Pérez JJ; López-Berges MC; Gutiérrez N; Ciudad J; Lucio P; Vazquez L; García-Sanz R; del Cañizo MC; Fernández-Calvo J; Ramos F; Rodríguez MJ; Calmuntia MJ; Porwith A; Orfao A; San-Miguel JF
    Blood; 2003 Jun; 101(12):4695-700. PubMed ID: 12586618
    [TBL] [Abstract][Full Text] [Related]  

  • 92. CD20 and Outcome of Childhood Precursor B-cell Acute Lymphoblastic Leukemia: A Meta-analysis.
    Ou DY; Luo JM; Ou DL
    J Pediatr Hematol Oncol; 2015 Apr; 37(3):e138-42. PubMed ID: 25222059
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Low EVI1 expression at diagnosis predicted poor outcomes in pediatric Ph-negative B cell precursor acute lymphoblastic leukemia patients.
    Yang L; Dao FT; Lu AD; Chen WM; Li LD; Long LY; Liu YR; Liu KY; Zhang LP; Qin YZ
    Pediatr Hematol Oncol; 2022 Mar; 39(2):97-107. PubMed ID: 34156313
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
    Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
    Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Nationwide study of pediatric B-cell precursor acute lymphoblastic leukemia with chromosome 8q24/MYC rearrangement in Japan.
    Sakaguchi K; Imamura T; Ishimaru S; Imai C; Shimonodan H; Fujita N; Okada K; Taketani T; Kanai R; Tauchi H; Kato M; Kojima Y; Watanabe A; Deguchi T; Hashii Y; Kiyokawa N; Taki T; Saito AM; Horibe K; Manabe A; Sato A; Koh K
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28341. PubMed ID: 32323914
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Che-1 is targeted by c-Myc to sustain proliferation in pre-B-cell acute lymphoblastic leukemia.
    Folgiero V; Sorino C; Pallocca M; De Nicola F; Goeman F; Bertaina V; Strocchio L; Romania P; Pitisci A; Iezzi S; Catena V; Bruno T; Strimpakos G; Passananti C; Mattei E; Blandino G; Locatelli F; Fanciulli M
    EMBO Rep; 2018 Mar; 19(3):. PubMed ID: 29367285
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: a study of five cases controlled by genetic methods.
    Dworzak MN; Stolz F; Fröschl G; Printz D; Henn T; Fischer S; Fleischer C; Haas OA; Fritsch G; Gadner H; Panzer-Grümayer ER
    Exp Hematol; 1999 Apr; 27(4):673-81. PubMed ID: 10210325
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Clinicians' Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study.
    Gidman W; Shah S; Zhang L; McKendrick J; Cong Z; Cohan D; Ottmann O
    Adv Ther; 2019 Nov; 36(11):3017-3029. PubMed ID: 31586302
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
    Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
    Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Deletion of CDKN2A/B is associated with inferior relapse free survival in pediatric B cell acute lymphoblastic leukemia.
    Kathiravan M; Singh M; Bhatia P; Trehan A; Varma N; Sachdeva MS; Bansal D; Jain R; Naseem S
    Leuk Lymphoma; 2019 Feb; 60(2):433-441. PubMed ID: 29966470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.